ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 135 entries already.
Sensorion has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as its lead gene therapy program after filing clinical trial applications in France and Canada. The French biotech is discontinuing development of its OTOF-targeted therapy SENS-501, citing a changed competitive environment following the approval of Regeneron’s rival gene therapy.
Oslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward IND-enabling development and clinical proof-of-concept.
Boehringer Ingelheim has reported new Phase III data for survodutide, its once-weekly dual GLP-1/glucagon receptor agonist for obesity, highlighting reductions in body weight, visceral fat and liver fat. The results, presented at the American Diabetes Association Scientific Sessions, strengthen the company’s case that survodutide could offer a differentiated profile in metabolic disease, although gastrointestinal tolerability remains a key question.
Portuguese drugmaker BIAL has discontinued development of BIA 28-6156, also known as pariceract, after a Phase IIb study failed to show that the oral therapy could slow progression in patients with GBA-associated Parkinson’s disease. The readout marks a setback for one of the more advanced attempts to turn Parkinson’s genetics into a disease-modifying therapy.
London-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma partnership to its extracellular matrix-driven drug discovery platform.
Swiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies and potentially for immunology and neurology indications.
Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.
Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
Warsaw-based AI biology company Ingenix has raised €13m in a seed-extension financing round led by Sofinnova Partners, with participation from Inovo VC and OTB VC.
London-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.